324 related articles for article (PubMed ID: 2934477)
41. Killer-helper effect of L cells in the generation of anti-MM cytotoxic T lymphocytes: replacement by beta-interferon and mechanisms of action.
Ishikawa S; Tachibana T
Jpn J Cancer Res; 1986 Sep; 77(9):931-40. PubMed ID: 2945807
[TBL] [Abstract][Full Text] [Related]
42. Expression of Leu-19 (NKH-1) antigen on IL 2-dependent cytotoxic and non-cytotoxic T cell lines.
Lanier LL; Le AM; Ding A; Evans EL; Krensky AM; Clayberger C; Phillips JH
J Immunol; 1987 Apr; 138(7):2019-23. PubMed ID: 2951430
[TBL] [Abstract][Full Text] [Related]
43. Stimulation with autologous lymphoblastoid cell lines: lysis of Epstein-Barr virus-positive and -negative cell lines by two phenotypically distinguishable effector cell populations.
Zarling JM; Dierckins MS; Sevenich EA; Clouse KA
J Immunol; 1981 Nov; 127(5):2118-23. PubMed ID: 6170690
[TBL] [Abstract][Full Text] [Related]
44. Characterization of the in vitro sensitivity of human lymphoid and hematopoietic progenitors to L-leucyl-L-leucine methyl ester.
Pecora AL; Bordignon C; Fumagalli L; Radziejewski C; Small TN; Pekle K; O'Reilly RJ; Keever CA
Transplantation; 1991 Feb; 51(2):524-31. PubMed ID: 1994549
[TBL] [Abstract][Full Text] [Related]
45. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
46. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
47. Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: elimination of graft-versus-host disease without detrimental effects on engraftment.
Blazar BR; Thiele DL; Vallera DA
Blood; 1990 Feb; 75(3):798-805. PubMed ID: 1967541
[TBL] [Abstract][Full Text] [Related]
48. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
49. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
50. A large subpopulation of lymphocytes with T helper phenotype (Leu-3/T4+) exhibits the property of binding to NK cell targets and granular lymphocyte morphology.
Velardi A; Grossi CE; Cooper MD
J Immunol; 1985 Jan; 134(1):58-64. PubMed ID: 3155472
[TBL] [Abstract][Full Text] [Related]
51. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.
Damle NK; Doyle LV; Bradley EC
J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965
[TBL] [Abstract][Full Text] [Related]
52. Further dissection of the functional heterogeneity within the OKT4+ and OKT8+ human T cell subsets.
Thomas Y; Rogozinski L; Rothman P; Rabbani LE; Andrews S; Irigoyen OH; Chess L
J Clin Immunol; 1982 Jul; 2(3 Suppl):8S-14S. PubMed ID: 6215426
[TBL] [Abstract][Full Text] [Related]
53. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.
Miescher S; Whiteside TL; Moretta L; von Fliedner V
J Immunol; 1987 Jun; 138(11):4004-11. PubMed ID: 3108380
[TBL] [Abstract][Full Text] [Related]
54. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
55. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
56. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
57. Cytotoxicity by human adherent cells: oxygen-dependent and -independent cytotoxic reactions by different cell populations.
van Kessel KP; Visser MR; van Strijp JA; van Kats-Renaud JH; Verhoef J
Immunology; 1986 Jun; 58(2):291-6. PubMed ID: 3710525
[TBL] [Abstract][Full Text] [Related]
58. The role of leucyl-leucine methyl ester-sensitive cytotoxic cells in skin allograft rejection.
Thiele DL; Geissler GH; Williams FH; Lipsky PE
Transplantation; 1992 Jun; 53(6):1334-40. PubMed ID: 1604489
[TBL] [Abstract][Full Text] [Related]
59. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
Itoh K; Tilden AB; Kumagai K; Balch CM
J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
[TBL] [Abstract][Full Text] [Related]
60. Induction of cytolytic activity by anti-T3 monoclonal antibody. Activation of alloimmune memory cells and natural killer cells from normal and immunodeficient individuals.
Suthanthiran M; Williams PS; Solomon SD; Rubin AL; Stenzel KH
J Clin Invest; 1984 Dec; 74(6):2263-71. PubMed ID: 6392343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
